In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

Slides:



Advertisements
Similar presentations
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advertisements

Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Imaging modalities in prostate cancer
Carcinoma of the Prostate By: Ishan Parikh. Background on Cancer  Oldest information dates back to 3000 BC, Egyptian textbook on trauma surgery – “There.
Prostate Cancer Crisis: Imaging is the Solution Faina Shtern, MD President, AdMeTech Foundation.
CA of Prostate:Incidence In a 50 y/o man In a 50 y/o man In autopsy: 40% In autopsy: 40% Clinical: 10% Clinical: 10% Death: 3% Death: 3% Most common non-cutanous.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Expectant Management of Prostate Cancer James A. Eastham, MD and Peter T. Scardino, MD June 23, 2010 Presented by: K. Witzke, DO.
Steven Joniau Filip Ameye
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
David Anderson, Bruce Golden, Ed Wasil, Howard Zhang 1 INFORMS Healthcare 6/24/2013.
PET/CT & PET/MRI Radiopharmacy
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
David Anderson, Bruce Golden, Ed Wasil, Howard Zhang 1 INFORMS Annual Meeting October, 2013.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Guzman, Alexander Joseph Hipolito, April Lorraine
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Design of Clinical Trials for Select Patients With a Rising PSA following Primary Therapy Anthony V. D’Amico, MD, PhD Professor of Radiation Oncology Harvard.
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.
Active surveillance in prostate cancer Dr John Yaxley Urological & robotic surgeon.
The role of Endoscopy in Gastric Cancer Fergal Donnellan Gastroenterologist VGH.
ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.
MRI IN PROSTATE CANCER MAHYAR GHAFOORI M.D. Associate Professor of Radiology Tehran University Of Medical Sciences.
PET/MR in Oncology: Non– 18 F- FDG Tracers for Routine Applications R2 丁建鑫.
V. Scattoni mpMRI of the prostate: Does it change indications for biopsy and repeat biopsy?
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
IMAGING OF INCIDENTAL ADRENAL LESIONS: PRINCIPLES, TECHNIQUES AND ALGORITHMS Giles W.L. Boland Massachusetts General Hospital Harvard Medical School.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Gian Maria Busetto Sapienza Rome University Prostate cancer gene 3 (PCA3) and multiparametric magnetic resonance (mMRI) can reduce unnecessary biopsies:
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Utilizing MRI in Prostate Cancer Diagnosis and Fusion Biopsy Ari Goldberg MD,PhD Dept. Radiology Loyola University Medical Center.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.
What is Breast Cancer ? Abnormal cells develop from normal cells in the breast to form tumors Abnormal cells develop from normal cells in the breast to.
Manit Arya Consultant Urological Surgeon UCLH and PAH Transforming the Pathway in Prostate Cancer.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Volume 64, Issue 5, Pages (November 2013)
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer 
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.
Klinikum rechts der Isar, Technische Universität München
Indications for Breast MR Imaging
Surgical Treatment in Locally Advanced Prostate Cancer
Bladder Cancer and Prostatic Cancer
74-year-old man with stage T2a Gleason score prostate cancer (prostate specific antigen = ng/mL) in right transition zone (TZ) with history.
Prostate cancer นพ.ชัชชัย หอมเกตุ.
Gian Maria Busetto Sapienza Rome University
Nat. Rev. Urol. doi: /nrurol
New Tracers for Prostate Cancer Imaging
Staging Cancer.
Prostate Cancer: Highlights from 2006
Apollo Gleneagles Hospitals,
Volume 67, Issue 3, Pages (March 2015)
Volume 54, Issue 3, Pages (September 2008)
Volume 64, Issue 6, Pages (December 2013)
Volume 64, Issue 5, Pages (November 2013)
Volume 62, Issue 1, Pages (July 2012)
Nat. Rev. Urol. doi: /nrurol
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Prostate Cancer Update
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
Presentation transcript:

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection rate of 81% when PSA dt is less than 3 months 3- it best identifies patients with bone metastases 4- PET/CT is indicated for pre-op staging in case of suspicious MRI

2-A negative Choline PET/CT is not sufficient to rule out the indication for lymph-adenectomy a-true b-false

A 67 year old man has a T2b prostate cancer Gleason score 8, PSA: 8.7ng/ml. mpMRI shows extracapsular extension on the right, no enlarged lymph nodes 1- a bone scan is necessary 2- bone scan is more accurate for osteoclastic lesions 3- mp MRI of the prostate can detect all bone metastases 4- DW total body MRI is more sensitive than bone scan to R/O bone metastases

The use of choline PET/CT for preoperative LN staging: 1- is indicated 2- high sensitivity but poor specificity 3- should be limited to patients with very high risk for LN positive status according to nomograms 4- has a low positive predicted value

PET choline for detection of LN and distant recurrence in PC patients with biochemical recurrence 1- Significantly high detection rate with PSA <1 ng/ml 2- The Trigger PSA value is = or > 5g/ml 3- No relationship between detection rate and PSA kinetics 4- A crucial role as first diagnostic procedure in patients who demonstrate a fast growing PSA kinetics and low Trigger PSA

choline PET/CT 1- could play a crucial role as first diagnostic procedure in PC patients 2- It is not recommended for initial diagnosis and staging as a first-line method 3- PSA dt could not be considered as an independent predictor of positive choline PET/CT 4- 18f choline PET/CT is not accurate to detect distant recurrence

Dynamic Contrast Study 1.Based on density of tumor cells 2.Early enhancement of tumoral tissue in T2- weighted MRI 3.Delayed wash out of contrast agent are seen in prostate cancer 4.Early enhancement of tumoral tissue in T1 - weighted MRI

Diffusion Weighted Imaging 1.Works based on angiogenesis 2.Water molecules movement increases in a high cellular environment 3.Sensitivity and specificity of DWI when added to T2-Weighted MRI for detecting prostate cancer is about 84% and 87% respectively 4.DW-MR imaging alone shows high sensitivity in cancer recurrence detection after radiotherapy

MR Spectroscopy 1.Combination of choline and fluorocholine is measured in MRS 2.Citrate accumulates in the T zone 3.Citrate is higher in malignant prostatic tissue 4.A higher ratio of Cho+Cr/Ci (more than 0.75 ) is in favor of high risk of malignancy

Regarding the use of Multiparametric MR imaging select the wrong answer Detection and local staging of prostate cancer Follow-up of patients after radical prostatectomy or radiation therapy Detection of skeletal metastasis Targeting biopsies in patients suspicious of prostate cancer